{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 42,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Slide includes two charts: a stacked bar chart for sales growth and a stacked bar chart for collaboration revenue.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/12",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.03,
        "y": 0.26
      },
      "kind": "chart",
      "text": "34% growth in sales to $1.1bn",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25510f4a-6304-4e85-beaa-5e29e6ab3603",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.67,
        "y": 0.26
      },
      "kind": "chart",
      "text": "Collaboration revenue",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52c65f27-b328-4d9b-897f-b700893d8284",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.67,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Collaboration revenue at actual exchange rates. Collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada. $3.1bn revenue recorded; $4.6bn future potential.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4fe9f5b7-e87a-4bb8-821c-0f72a72b4a7a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.3,
        "x": 0.03,
        "y": 0.88
      },
      "kind": "disclaimer",
      "text": "Product sales at actual exchange rates; changes at CER and for H1 2021, unless stated otherwise. 1. Poly ADP ribose polymerase. 2. Ovarian cancer.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4e46937-cbd1-48a4-b011-d6b53810ab8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.35,
        "y": 0.26
      },
      "kind": "list",
      "text": "Approvals 84 (ovarian), 82 (breast), 63 (pancreatic) and 60 (prostate cancer). US +29%, Europe +38%, EM +50%, ERoW +26%.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6e7da3e4-2c2e-4920-84aa-40ac4cacc367",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Lynparza: The globally-leading PARP inhibitor",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fcafb704-59f7-42f2-a4a1-18dea845d7a4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Big Idea Formula",
      "slug": "big-idea-formula",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "e7941894-e4ff-43ca-9396-380398a33265",
      "evidence": "disclaimer: Collaboration revenue at actual exchange rates. Collaboration with Merck & Co., Inc., Kenilworth, NJ, US, known as MSD outside the US and Canada. $3.1bn revenue recorded; $4.6bn future potential.",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 11,
      "beatId": "4d44e7fe-d7a8-49cd-a7ca-8ebf40e8c11e",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The document provides detailed KPI overviews and key messages",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 6,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "0370e540-f8fc-47e8-893d-8aa1d6254971",
      "evidence": "The document presents a pattern of growth and innovation across various therapeutic areas",
      "position": 0,
      "objective": "Highlighting growth drivers and pipeline progress",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}